Decreases in T-cell tumor necrosis factor α binding with interferon beta treatment in patients with multiple sclerosis

Archives of Neurology

Volumn 56, Issue 1, 1999, Pages 71-78

  Bongioanni, Paolo ^a   Mosti, Serena ^a   Moscato, Gianluca ^a   Lombardo, Francesco ^a   Manildo, Chiara ^b   Meucci, Giuseppe ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CALCIUM IONOPHORE; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE OF ONSET; BINDING, COMPETITIVE; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN BINDING; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032905157     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.1.71     Document Type: Article

References (89)

1. O'Gorman M, Oger J. Cell-mediated immune functions in multiple sclerosis. Pathol Immunopathol Res. 1987;6:241-272.
2. Hartung H-P. Neurological progress: immune-mediated demyelination. Ann Neurol. 1993;33:563-567.
3. Ransohoff RM, Benveniste EN. Cytokines and the CNS. London, England: CRC Press Inc; 1996:31-102.
4. Aggarwal BB. Tumor necrosis factor In: Gutterman JU, Aggarwal BB, eds. Human Cytokines: Handbook for Basic and Clinical Researchers. New York, NY: Blackwell Scientific Publishers; 1992:270-285.
5. Nicola NA. Guidebook to Cytokines and Their Receptors. Oxford, England: Oxford University Press; 1994:162-194.
6. Raine CS. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol. 1994;36(suppl 4):S61-S72.
7. Bongioanni P. Tumor necrosis factor induces class II major histocompatibility complex antigen expression on cultured rat type-1 astrocytes. J Chemother. 1991;3:32-34.
8. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw. 1992;3:523-531.
9. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995;37:82-88.
10. Rieckmann P, Martin S, Weichselbraun I. et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator tor relapse. Neurology. 1994;44:2367-2372.
11. Hartung H-P, Reiners K, Archelos JJ. et al. Circulating adhesion molecules and TNF receptor in MS: correlation with MRI. Ann Neurol. 1995;37:289-297.
12. Smith RA, Baglioni C. Characterization of TNF receptors. In: Aggarwal BB, Vilcek J, eds. Tumor Necrosis Factor: Structure, Function and Mechanism of Action. New York, NY: Marcel Dekker Inc; 1992:131-148.
13. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics. 1992;13:219-224.
14. Dembic Z, Loetscher U, Gubler U, et al. Two human TNF receptors have similar extracellular, but distinct intracellular domain sequences. Cytokine. 1990;2:231-237.
15. Jacobs L, O'Malley J, Freeman A, Murawski J, Ekes R. Intrathecal interferon in multiple sclerosis. Arch Neurol. 1982;39:609-615.
16. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma Interferon: exacerbations associated wth activation of the immune system. Neurology. 1987;37:1097-1102.
17. Huber M, Bamborschke S, Assheuer J, Heiss WD. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and CSF/MRI findings. J Neurol. 1988;235:171-173.
18. Jacobs L, Salazar AM, Herndon R, et al. Multicenter double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet. 1986;2:1411-1414.
19. Milanese C, Salmaggi A, La Mantia L, et al. Double-blind study of intrathecal beta- interferon in multiple sclerosis: clinical and laboratory results. J Neurol Neurosurg Psychiatry. 1990;53:554-557.
20. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:655-661.
21. Jacobs L, Cookfair D, Rudick R, et al, and the MS Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
22. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:662-667.
23. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology. 1993; 43:2080-2087.
24. 1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurology. 1996;46:1633-1638.
25. 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int J Neurosci. 1997;90:135-144.
26. 1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996;1:262-269.
27. Petereit HF, Bamborschke S, Esse AD, Heiss WD. Interferon gamma producing blood lymphocytes are decreased by inteferon beta therapy in patients with multiple sclerosis. Mult Scler. 1997;3:180-183.
28. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine detection by flow cytometry and surface marker analysis. Clin Diagn Lab Immunol. 1996;3:411-416.
29. 1b. Neurology. 1995;45:2173-2177.
30. 1b therapy. J Clin Invest. 1997;99:2664-2671.
31. 1b. Ann Neurol. 1997;41:669-674.
32. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is down-regulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997;49:1111-1116.
33. Bongioanni P, Meucci G. T-cell tumor necrosis factor-α receptor binding in patients with multiple sclerosis. Neurology. 1997;48:826-831.
34. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria tor multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
35. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
36. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
37. Quality Standards Committee. American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology. 1994;44:1537-1540.
38. Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989;25:172-178.
39. Bertouch JV, Roberts-Thompson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. BMJ. 1983;286:1771-1772.
40. Aggarwal BB, Kohr WJ. Human tumor necrosis factor. Methods Enzymol. 1985;116:450-451.
41. McPherson GA. Kinetic, EBDA, Ligand, Lowry: A Collection of Radioligand Binding Analysis Programs. Amsterdam, the Netherlands: Elsevier Science Ltd: 1985.
42. Brockhaus M, Schönfeld HJ, Schläger EJ, Hunziger W, Lesslauer W, Lötscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87:3127-3131.
43. Noronha A, Richman DP, Arnason BG. Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980;303:713-717.
44. Golaz J, Steck A, Moretta L. Activated T lymphocytes in patients with multiple sclerosis. Neurology. 1983;33:1371-1373.
45. Brinkman CJ, Nillesen WM, Hommes OR. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Clin Immunol Immunopathol. 1983;29:341-348.
46. Hafler DA, Fox DA, Manning ME, et al. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985;312:1405-1411.
47. Selmaj K, Plater-Zyberk C, Rockett KA, et al. Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes. Neurology. 1986;36:1392-1395.
48. Konttinen YT, Bergroth V, Kinnunen E, Nordström D, Kouri T. Activated T lymphocytes in patients with multiple sclerosis in clinical remission. J Neurol Sci. 1987;81:133-139.
49. Corrigan E, Hutchinson M, Feighery C. Fluctuations in T helper subpopulations in relapsing-remitting multiple sclerosis. Acta Neurol Scand. 1990;81:443-447.
50. Ofosu-Appiah W, Mokhtarian F, Miller A, Grob D. Characterization of in vivo- activated T cell clones from peripheral blood of multiple sclerosis patients. Clin Immunol Immunopathol. 1991;58:46-55.
51. Calopa M, Bas J, Mestre M, Arbizu T, Peres J, Buendia E. T cell subsets in multiple sclerosis: a serial study. Acta Neurol Scand. 1995;92:361-368.
52. Bongioanni P, Fioretti C, Vanacore R, et al. Lymphocyte subsets in multiple sclerosis: a study with two-colour fluorescence analysis. J Neurol Sci. 1996;139:71-77.
53. Bongioanni P, Lombardo F, Fioretti C. Meucci G. T-lymphocyte immunointerferon receptors in patients with multiple sclerosis J Neurol. 1996;243:605-610.
54. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T-cell responses. J Immunol. 1987;138:1786-1790.
55. Ware CF, Crowe PD, Vanarsdale TL, et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes: differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol. 1991;147:4229-4238.
56. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 1993;151:4637-4641.
57. Munker R, Di Persio J, Koeffler HP. Tumor necrosis factor: receptors on hematopoietic cells. Blood. 1987;74:1730-1734.
58. Santis AG, Campanero MR, Alonso JL, Sanchez-Madrid F. Regulation of tumor necrosis factor (TNF)-α synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway Eur J Immunol. 1992;22:3155-3160.
59. Hall GL, Wing MG, Compston DA, Scolding NJ. Beta-interferon regulates the immunomodulatory activity of neonatal rodent microglia. J Neuroimmunol. 1997;72:11-19.
60. 1b on primary human neural cells. Mult Scler. 1995;1:10-19.
61. Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989;23:45-53.
62. Ransohoff RM, Devajyothi C, Estes ML, et al. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol. 1991;33:103-112.
63. Satoh J, Paty DW, Kim SU. Counteracting effect of IFN-β on IFN-γ-induced proliferation of human astrocytes in culture. Mult Scler. 1996;1:279-287.
64. Garotta G, Talmadge KW, Pink JR, Dewald B, Baggiolini M. Functional antagonism between type I and type II interferons on human macrophages. Biochem Biophys Res Commun. 1986;140:948-954.
65. Deguchi M, Inaba K, Muramatsu S. Counteracting effect on interferon-α and -β on interferon-γ-induced production of nitric oxide which is suppressive for antibody response. Immunol Lett. 1995;45:157-162.
66. Stewart VC, Giovannoni G, Land JM, McDonald WI, Clark JB, Heales SJ. Pretreatment of astrocytes with interferon-α/β impairs interferon-γ induction of nitric oxide synthase. J Neurochem. 1997;68:2547-2551.
67. Huynh HK, Oger J, Dorovini-Zis K. Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol. 1995;60:63-73.
68. Goodall CA, Curtis AS, Lang SC. Modulation of adhesion of lymphocytes to murine brain endothelial cells in vitro: relation to class II major histocompatibility complex expression. J Neuroimmunol. 1992;37:9-22.
69. Soilu-Hanninen M, Salmi A, Salonen R. Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol. 1995;60:99-106.
70. Svenningsson A, Hansson GK, Andersen O, Andersson R, Patarroyo M, Stemme S. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. Ann Neurol. 1993.34:155-161.
71. 1b on cytokine-induced adhesion molecule expression. Neurochem Int. 1997;30:449-453.
72. Noronha A, Toscas A, Jensen MA. Interferon β decreases T-cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol. 1993;46:145-154.
73. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996;67:111-118.
74. 1b on the immune response to myelin basic protein. J Neuroimmunol. 1995;61:185-193.
75. Pette M, Pette DF, Muraro PA, Farnon E, Martin R, McFarland HF. Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific. T-helper type 1 lymphocytes. Neurology. 1997;49:385-392.
76. Rudick RA, Ransohoff RM, Peppler R, Medendrop Vander-Brug S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996;40:618-627.
77. Taga K, Tosato G. IL-10 inhibits human T-cell proliferation and IL-2 production. J Immunol. 1992;148:1143-1148.
78. Noronha A, Jensen MA, Toscas A, Sihag S. IFN-beta down-regulates tumor necrosis factor release. Neurology. 1992;42(suppl 3):159-160.
79. Abu-khabar KS, Armstrong JA, Ho M. Type I interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol. 1993;52:165-172.
80. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996;40:853-863.
81. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40:846-852.
82. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
83. Spear GT, Paulnock DM, Jordan RL, Meltzer DM, Merritt JA, Borden EC. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol. 1987;69:107-115.
84. Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by Interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst. 1989;81:1061-1068.
85. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995;61:27-34.
86. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990;27:207-210.
87. Panitch HS. Folus JS, Johnson KP. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS. Neurology. 1989;39(suppl 1):171-172.
88. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol. 1997;10:186-192.
89. Aggarwal BB, Eessalu TE, Mass PE. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 1985;318:665-667.